Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Sagimet Biosciences Inc.

NASDAQ: SGMT · Life Sciences · 5 alerts · CIK 1400118

Share price
$10.13Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Sagimet Biosciences Inc. filings on SEC EDGAR ↗

7:49 AM ET 8-K
Financial Results

Sagimet Biosciences Financial Results

Sagimet Biosciences reported third quarter 2026 financial results and provided a corporate update on its Phase 3 AURORA clinical trial for denifanstat in moderate to severe acne. The company highlighted a pro forma cash position of $356 million following a $115 million equity financing in October, which is expected to fund operations through mid-2029.

“Building on the positive Phase 3 results from our license partner Ascletis, we have initiated our pivotal U.S. AURORA Phase 3 clinical trial. With our October equity financing, we are well positioned to fund our programs through mid-2029, including the anticipated Phase 3 denifanstat data readout and the potential submission of an NDA.”

David Happel, Chief Executive Officer
7:31 AM ET 10-Q
Financial Results

Sagimet Biosciences Q3 2026 Results: Net Loss of $19.1M, Loss Widens

Sagimet Biosciences Inc. reported a significant increase in total assets to $282.1 million as of September 30, 2026, up from $116.5 million at the end of 2025, primarily driven by growth in cash and marketable securities. The company is advancing its lead drug candidate, denifanstat, through clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Current liabilities also increased to $38.0 million, including a $27.5 million liability for proceeds received for equity not yet issued.

Key figure
Net loss $19.1M
7:16 AM ET 8-K
Investor Presentation

Sagimet Biosciences Investor Presentation

Sagimet Biosciences Inc. has updated its corporate investor presentation, which will be used by management in upcoming meetings with investors. The presentation, filed as Exhibit 99.1, provides an overview of the company's novel therapeutics targeting metabolic dysfunction, including its lead candidate denifanstat.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.